Effective February 20, 2024, Foquest is listed on the New Brunswick Formulary (special authorization) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD).
Learn more about the eligibility criteria for reimbursement of Foquest in New Brunswick.
